Form 4: Colgate-Palmolive Director Bilbrey Acquires Additional Shares
SEC Form 4 Filing
Director John P. Bilbrey acquired 201 shares of Colgate-Palmolive common stock at $105.24 per share on October 1, 2024, according to a recent SEC filing.
Summary
- On October 1, 2024, John P. Bilbrey, a director of Colgate-Palmolive, acquired 201 shares of common stock at a price of $105.24 per share.
- The acquisition was made through a portion of his annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
- Following the transaction, Bilbrey directly owns 32,879 shares of Colgate-Palmolive common stock and indirectly owns 4,719 shares through a trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. While insider buying can be seen as a positive signal, this is part of a pre-arranged plan.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. This purchase by a director is a routine transaction related to deferred compensation.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of transaction: John P. Bilbrey acquired 201 shares of Colgate-Palmolive common stock. |
| 10/03/2024 | Date of filing: The SEC Form 4 was signed on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.